Affiliation:
1. Tianjin Medical University Cancer Institute & Hospital
Abstract
Abstract
Sialic acid-binding immunoglobulin-like lectin 15 (Siglec-15) is an immune checkpoint molecule with sequence homology to programmed cell death ligand 1 (PD-L1), which is mainly expressed on macrophages and tumor cells. However, whether Siglec-15 induced immunosuppression and poor prognosis are independent of PD-L1 remains unclear. In this study, we collected samples of 135 non-small cell lung cancer and found that Siglec-15 and PD-L1 expression were independent in non-small cell lung cancer by multiple immunofluorescence staining. Siglec-15 on macrophages (Mφ-Siglec-15) was significantly associated with DFS (p < 0.05) in PD-L1- patients with non-metastasis lung adenocarcinoma, not in PD-L1+ or lung squamous cell carcinoma patients. Moreover, stromal Siglec-15+ macrophages of Mφ-Siglec-15+PD-L1- patients were significantly more than those of Mφ-Siglec-15-PD-L1- patients (p = 0.002). We further found that Siglec-15+ macrophages were negatively associated with inflamed immunophenotype in PD-L1- patients and may inhibit CD8+T cells infiltration, validated in another independent cohort and in vivo. In conclusion, PD-L1-independent Siglec-15+ macrophages contribute to the formation of immunosuppressive microenvironment in non-metastasis lung adenocarcinoma patients, which may cause a higher risk of recurrence. Siglec-15 could be a potential target for normalizing cancer immunotherapy, benefiting patients who fail to respond to anti-PD-L1 therapy.
Publisher
Research Square Platform LLC
Reference30 articles.
1. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations;Zou W;Sci Transl Med,2016
2. Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation;Wu M;J Hematol Oncol,2022
3. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries;Sung H;CA Cancer J Clin,2021
4. Lung cancer: some progress, but still a lot more to do;The L;Lancet (London, England),2019
5. PD-L1 in non-small-cell lung cancer: the third target for immunotherapy;Smit EF;Lancet (London, England),2016